About the TAPUR Study

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. The study provides approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies, catalogues the choice of genomic profiling test by clinical oncologists and aims to learn about the utility of registry data to develop hypotheses for additional clinical trials. To find responses to commonly asked questions, please visit our FAQ page and review our patient brochure.

Who Benefits?

Study participants get access to targeted drugs matched to the genomic profiles of their tumors.

Physician investigators receive assistance interpreting genomic test results and identifying appropriate treatments.

Cancer community learns about new uses of targeted anti-cancer drugs for patients who have exhausted current options.

Pharmaceutical companies get data on use of drugs for possible new cancer indications already being used in clinical practice.

Regulators get data about adverse events and other outcomes.

TAPUR Study News

ASCO Expands TAPUR Study Enrollment After Promising Initial Treatment

The American Society of Clinical Oncology’s (ASCO) Targeted Agent and Profiling Utilization Registry (TAPUR) Study has expanded four cohorts for enrollment of additional participants and continues to grow with more than 500 participants and 16 therapies now available. Additionally, eight new centers in 36 locations signed on to begin offering the TAPUR Study at their locations within the next few months. This brings the total number of TAPUR sites to 101 in 20 states. 


ASCO’s TAPUR Study Continues its Expansion of Sites, Participants, and Collaborators

ASCO's TAPUR Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. Additionally, in an effort to expand eligibility and facilitate logistics, the TAPUR Study is engaging in several new collaborations.


More Than 100 Participants Enrolled; 25 New Clinical Sites; Lowering Enrollment Age

ASCO announced that 105 participants have are now enrolled on the TAPUR Study. An additional 25 clinical sites are being brought onto the study, increasing the total number of enrolling TAPUR locations to 63 sites. ASCO also announced plans to decrease the enrollment age from 18 to 12 years to extend the opportunity for participation to adolescent patients with advanced cancer.


Network of Centers

TAPUR is now enrolling patients at cancer centers and networks across the country. Additional sites will be brought on in 2018.